Clinical Report: Advanced Crohn’s Therapies Show Similar Safety
Overview
A large analysis of over 12,000 Crohn’s disease patients revealed similar safety profiles among various biologics and a Janus kinase inhibitor. No significant differences were found in serious infections, venous thromboembolism, or major adverse cardiovascular events over approximately 27 months.
Background
Understanding the safety profiles of advanced therapies for Crohn's disease is crucial for clinicians as they navigate treatment options for patients. With multiple biologics and small molecules available, assessing safety is essential to optimize patient outcomes and minimize risks. This study provides valuable insights into the comparative safety of these therapies in a real-world setting.
Data Highlights
| Therapy | Serious Infections (per 100 person-years) | Venous Thromboembolism (per 100 person-years) | Major Adverse Cardiovascular Events (per 100 person-years) |
|---|---|---|---|
| All Therapies | 5-9 | ~1 | <2 |
Key Findings
- No significant differences in serious infections across therapies.
- Ustekinumab showed a lower risk of gastrointestinal serious infections compared to vedolizumab.
- Venous thromboembolism rates were low, around 1 event per 100 person-years.
- Major adverse cardiovascular events were uncommon, with rates below 2 events per 100 person-years.
- Janus kinase inhibitors had a lower risk of inpatient or emergency department events in a sensitivity analysis.
Clinical Implications
Clinicians can consider the broadly similar safety profiles of advanced therapies when making treatment decisions for Crohn's disease. The findings support the use of various biologics and Janus kinase inhibitors without significant concern for serious adverse events. Ongoing monitoring and individualized patient assessment remain essential.
Conclusion
This study underscores the comparable safety of advanced Crohn’s therapies, providing reassurance for clinicians in their treatment choices. Further research may be needed to explore long-term outcomes and the impact of newer agents.
References
- Comparative Safety of Advanced Therapies for Crohn Disease | Gastroenterology and Hepatology | JAMA Network, 2026 -- Advanced Crohn’s Therapies Show Similar Safety
- The New Gastroenterologist — Assessing the Risk-Benefit Ratio of Upadacitinib for Inflammatory Bowel Disease, 2025 -- Evaluating the Benefit/Risk Profile of Upadacitinib in IBD
- The New Gastroenterologist — New Crohn's data spotlight promising therapies, 2026 -- New Crohn's Data Spotlight Promising Therapies
- The New Gastroenterologist — Choosing Treatment Options for Moderate to Severe Inflammatory Bowel Disease: Essential Considerations in the Decision-Making Process, 2025 -- Selecting Therapies in Moderate to Severe Inflammatory Bowel Disease
- ACG Clinical Guideline: Management of Crohn’s Disease in Adults, 2025 -- ACG Clinical Guideline on Crohn's Disease
- The New Gastroenterologist — Impact of Prior Anti-TNF Treatment on the Effectiveness of Subsequent Ulcerative Colitis Therapies
- ACG Clinical Guideline: Management of Crohn’s Disease in Adults
- Comparative Safety of Advanced Therapies for Crohn Disease | Gastroenterology and Hepatology | JAMA Network Open | JAMA Network
- Long-Term Safety of Upadacitinib in Patients With Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 Studies - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
